硒酸酯多糖对癌症患者血清MDA含量及CuZn-SOD活性的影响

目的：了解硒酸酯多糖对肿瘤患者体内ＭＤＡ及ＣｕＺｎ－ＳＯＤ活性的影响。方法：对６０例肿瘤病人随机分成３组：不服硒组，服硒４００μｇ／ｄ组及服８００μｇ／ｄ组并与１５名正常人对照比较。结果：癌症患者血清ＭＤＡ明显高于正常人（Ｐ＜０．０１），血清Ｓｅ及ＣｕＺｎ－ＳＯＤ活性明显低于正常人（Ｐ＜０．０１，Ｐ＜０．０５）；服硒酸酯多糖者化疗后血清Ｓｅ较不服者明显升高（Ｐ＜０．０５），ＣｕＺｎ－ＳＯＤ也明显升高（Ｐ＜０．０１），ＭＤＡ含量显著下降（Ｐ＜０．０５）；服４００μｇ／ｄ组与服８００μｇ／ｄ组之间上述各指标均无明显差异。结论：肿瘤病人摄入适量（４００μｇ／ｄ）硒酸酯多糖可能增加体内ＣｕＺｎ－ＳＯＤ活性，减轻了化疗药物对正常细胞的过氧化损伤。     

急性白血病患者血清Mn—SOD和Cu·Zn—SOD活力的初探

采用亚硝酸盐法测定３０例正常人和５０例急性白血病患者血清ＳＯＤ活力变化，结果正常人ＳＯＤ总活力９４．４３±１４．５６Ｎｕ／ｍｌ，Ｍｎ－ＳＯＤ／Ｃｕ·Ｚｎ－ＳＯＤ比值０．５３±０．１６。初分析，急性白血病患者ＳＯＤ总活力７９．７９±２９．７６Ｎｕ／ｍｌ，比正常人明显下降（Ｐ＜０．０５），而Ｍｎ－ＳＯＤ／Ｃｕ·Ｚｎ－ＳＯＤ比值则较正常人明显升高（Ｐ＜０．０１），缓解期患者ＳＯＤ总活力和Ｍｎ－ＳＯＤ／Ｃｕ·Ｚｎ－ＳＯＤ比值分别为９１．５４±２１．５２Ｎｕ／ｍｌ和０．４６±０．２９均接近正常水平（Ｐ＞０．０５）。在综合分析各种ＳＯＤ活力的基础上，表明白血病患者血清ＳＯＤ变化与疾病的发生和发展有关。     

中华眼镜蛇毒对荷人鼻咽癌裸鼠血浆MDA和SOD的影响

目的：为了探讨中华眼镜蛇毒（ＮＮＡＶ）对荷人鼻咽癌（ＮＰＣ）裸鼠血浆丙二醛（ＭＤＡ）和超氧化物歧化酶鼠血浆ＭＤＡ和ＳＯＤ活性。结果：荷瘤鼠血浆ＭＤＡ（８．４２ｎｍｏｌ／ｍｌ）比正常裸鼠（３．９２ｎｍｏｌ／ｍｌ）明显升高，而荷瘤鼠血浆总ＳＯＤ（Ｔ－ＳＯＤ）、锰ＳＯＤ（Ｍｎ－ＳＯＤ）和铜锌ＳＯＤ（ＣｕＺｎ－ＳＯＤ）活性（５２．１９Ｎｕ／ｍｌ，２０．３１Ｎｕ／ｍｌ，３１．８８Ｎｕ／ｍｌ）比正常裸鼠（１２     

食管癌,胃癌患者血清和组织中CuZn—SOD—1含量观察

应用双抗体放射免疫分析法测定２５例食管癌、２０例胃癌血清ＣｕＺｎ－ＳＯＤ－１含量，发现其含量显著高于慢性胃炎（ｎ＝２８）及正常人（ｎ＝１７）（Ｐ＜０．０１）。血清ＣｕＺｎ－ＳＯＤ－１含量也明显高于良性组织（Ｐ＜０．０５）。组织ＣｕＺｎ－ＳＯＤ－１含量与血清ＣｕＺｎ－ＳＯＤ－１浓度呈显著正相关（ｒ＝０．７９６，ｎ＝２３，Ｐ＜０．００５）。表明ＣｕＺｎ－ＳＯＤ－１可望成为一种新的消化道肿瘤标志物，并可     

肺癌患者血清氧自由基清除剂含量的测定

同时检测了７２例原发性肺癌、３３例肺良性疾病和３５例健康人血清中总超氧化物歧化酶（Ｔ－ＳＯＤ）、铜锌超氧化物歧化酶（ＣｕＺｎ－ＳＯＤ），锰超氧化物歧化酶（Ｍｎ－ＳＯＤ），铜蓝蛋白（ＣＰ）活力及尿酸（ＵＡ）含量。肺癌血清Ｍｎ－ＳＯＤ及ＵＡ水平显著高于肺良性疾病和健康组（Ｐ＜０．０１）。Ｍｎ－ＳＯＤ对肺癌诊断的敏感性为８６．１１％，特异性为９１．１８％，诊断正确率为８８．５７％。晚期肺癌患者Ｍｎ－ＳＯＤ活力高于早期病人（Ｐ＜０．０５），８例肺癌手术后Ｔ－ＳＯＤ及Ｍｎ－ＳＯＤ明显下降（Ｐ＜０．０１）。Ｍｎ－ＳＯＤ与ＵＡ并联检测敏感性为９４．４４％，特异性为８５．２９％，诊断正确率为９０％。Ｍｎ－ＳＯＤ、ＵＡ和ＣＰ全部测定时敏感性则为９７．２２％，特异性为７７．９４％，诊断正确率为８７．８６％。结果提示，肺癌患者血清氧自由基清除剂水平增高。对肺癌诊断、鉴别诊断、病情分析及手术疗效监测起重要作用。     

食管癌、胃癌患者血清和组织中CuZn－SOD－1含量观察

应用双抗体放射免疫分析法测定２５例食管癌、２０例胃癌血清Ｃｕｚｎ－ＳＯＤ－１含量，发现其含量显著高于慢性胃炎（ｎ＝２８）及正常人（ｎ＝１７）（Ｐ＜０．０１）。血清ＣｕＺｎ－ＳＯＤ－ｌ含量在正常人、慢性胃炎、慢性胃炎伴肠上皮化生及胃癌序列中依次递增。２６例癌组织ＣｕＺｎ－ＳＯＤ－ｌ含量也明显高于良性组织（Ｐ＜０．０５）。组织ＣｕＺｎ－ＳＯＤ－ｌ含量与血清ＣｕＺｎ－ＳＯＤ－１浓度呈显著正相关（ｒ＝０．７９６，ｎ＝２３，ｐ＜０．００５）。表明ＣｕＺｎ－ＳＯＤ－ｌ可望成为一种新的消化道肿瘤标志物，并可作为监测胃癌危险人群的一种辅助手段。     

榄香烯对肺癌患者血液SOD活性和LPO浓度的影响研究

２５例晚期肺癌患者使用榄香烯３００ｍｇ＋生理盐水５００ｍｌ静脉滴注达１０天。使用前测定结果，Ｐ－ＳＯＤ２１．７２±７．８３Ｕ／ｍｌ，Ｅ－ＳＯＤ１７２４．９１±１８６．３４Ｕ／ｇ．Ｈｂ，较正常对照组显著降低（Ｐ＜０．０１）；Ｐ－ＬＰＯ１３．４７±１．９９μｍｏｌ／Ｌ，Ｅ－ＬＰＯ３９．８３±４．８３ｎｍｏｌ／ｇ．Ｈｂ，较正常对照组显著增高（Ｐ＜０．０１）。静脉使用榄香烯后，Ｐ－ＳＯＤ和Ｅ－ＳＯＤ活性明显改善，前、后对照有显著性差异（Ｐ＜０．０５），Ｅ－ＬＰＯ明显降低（Ｐ＜０．０５），Ｐ－ＬＰＯ恢复正常，和正常组相比较无显著性差异（Ｐ＞０．０５）。提示肺癌患者存在细胞抗氧化功能受损和脂质过氧化；榄香烯具有抗氧化功能，提高患者的免疫力，改善患者全身状况之功效     

白血病患者红细胞超氧化物歧化酶活性,血清过氧化脂质,维生素E…

本文观察了４４例白血病患者红细胞中铜、锌超氧化物歧化酶（ＲＢＣ·ＣｕＺｎ－ＳＯＤ）的活性、血清过氧化脂质（ＬＰＯ）和维生素Ｅ（ＶＥ）的水平，结果表明ＲＢＣ·ＣｕＺｎ－ＳＯＤ活性和ＬＰＯ水平在白血病患者中显著增高（Ｐ值均小于０．０１），而ＶＥ水平则明显降低（Ｐ〈０．０１）。对其中１５例急性白血病（ＡＬ）患者进行动态观察，在治疗获完全缓解后，其三者水平恢复到基本正常。反应了白血病患者体内存在着自由基产     

涎腺炎及良恶性混合瘤中铜锌超氧化物歧化酶免疫组化定位…

本文报道首次采用ＡＢＣ免疫组化法和免疫荧光直接法（单克隆抗体），对正常涎腺，涎腺炎及良恶性混合瘤的ＣｕＺｎＳＯＤ进行了检测。发现ＣｕＺｎＳＯＤ富集于涎腺导管上皮细胞和肌上皮细胞；良恶性混合瘤呈现不同程度的阳性反应，恶性混合瘤ＣｕＺｎＳＯＤ的阳性率及阳性反哟度均高于良性混合瘤，二者间差异有显著性（Ｐ＜０．０５）。结果提示：ＡＢＣ免疫组化法是检涎腺组织及良恶性混合瘤的ＣｕＺｎＳＯＤ的组化指标，，对涎腺     

食管癌手术前后SOD动态变化的临床观察

本文报告２０例食管癌患者手术前的超氧化物歧化酶（ＳＯＤ）动态变化的临床观察结果，提示：（１）术前总ＳＯＤ与术中和术后比较，有显著差异或非常显著差异（Ｐ〈０．０５或Ｐ〈０．０１）；（２）术中ＣｕＺｎＳＯＤ明显高于术前（Ｐ〈０．０１）；（３）ＭｎＳＯＤ在整个围术期无明显变化（Ｐ〉０．０５）。作者对这些变化的临床意义进行了讨论。     

Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20–54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT.     

Primary liposarcoma of the lung: Report of a case

We reported one case of a primary liposarcoma of the lung which has been reported only in six cases to date worldwide, and we added some documented study. A 49-year-old female complained of exertional dyspnea with about 100 ml of hemoptysis. The chest X ray showed a coin lesion at the left upper field. After left pneumonectomy, the histological examination revealed liposarcoma of the lung. Six months after the operation, she died from severe dyspnea; the autopsy revealed the relapse of liposarcoma in the right lung, and no liposarcomas in other organs. This is the seventh case according to a worldwide review of the literature.     

Amylase-producing lung cancer

A bronchioloalveolar carcinoma of lung associated with hyperamylasemia occurring in a 40-year-old woman is described. Another 13 cases of such a tumor from the English literature are reviewed. A majority of the lung tumors associated with hyperamylasemia were adenocarcinomas. When the amylase isoenzymes were determined, the amylase appeared to be salivary-gland type (S-type). Electron microscopic studies had revealed membrane-bound electron-dense granules within the tumor cells.     

Lymphadenectomy during pulmonary metastasectomy: Impact on survival and recurrence

Background and Objectives: Lymphadenectomy during pulmonary metastasectomy (PM) is widely carried out. We assessed the potential benefit on patient survival and tumor recurrence of this practice. Methods: One hundred eighty-one patients undergoing a first PM were studied. Eighty-six patients (47.5%) underwent lymphadenectomy (L+ group) whereas 95 (52.5%) did not undergo nodal harvesting (L−group). Main outcomes were overall survival (OS) and disease-free survival (DFS). Median follow-up was 25 months (interquartile range [IQR], 13-49). Results: At follow-up 84 patients (46.4%) died, whereas 97 (53.6%) were still alive with recurrence in 78 patients (43%). There was no difference in 5-year survival (L+ 30.0% vs L− 43.2%; P = .87) or in the 5-year cumulative incidence of recurrence (L + 63.2% vs L−80%; P = .07) between the two groups. Multivariable analysis indicated that disease-free interval (DFI) less than 29 months (P < .001) and lung comorbidities (P = .003) were significant predictors of death. Metastases from non-small–cell lung cancer increased the risk of lung comorbidities by a factor of 19.8, whereas the risk of DFI less than 29 months was increased nearly 11-fold. Competing risk regression identified multiple metastases (P = .004), head/neck primary tumor (P = .009), and age less than 67 years (P = .024) as independent risk factors for recurrence. Conclusion: Associated lymphadenectomy showed not to give any additional advantage in terms of survival and recurrence after PM.     

NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort

BackgroundNaPi2b is a multi-transmembrane sodium-dependent phosphate transporter expressed at normal levels in several organs, including lung. High expression levels have been reported in various tumors including breast, thyroid, ovarian and non-small cell lung cancer. To date evaluation of NaPi2b expression has mostly been restricted to smaller lung cancer cohorts.MethodsAnalyses were performed on archival formalin fixed paraffin embedded primary tumor specimens from patients who had undergone curative intent resection at an Australian tertiary hospital. Tissue microarrays were constructed and stained with the chimeric anti-NaPi2b antibody, MERS67. Semi-quantitative H-scores (range 0 – 300) were calculated for each core tissue sample (H-score = % tumor cells staining for NaPi2b multiplied by staining intensity). An overall average H-score was reported for each specimen, with a cut-off score of 50 considered positive.ResultsOf 438 cases, high NaPi2b expression was observed in 151 (34.5%) overall, high expression in 137 of 208 (65.9%) adenocarcinoma cases, and 5 of 179 (2.8%) squamous cases (P < .0001). High NaPi2b expression was associated with female sex, EGFR or KRAS mutation, and TTF1 positivity (adenocarcinoma cases only). High NaPi2b expression was associated with improved overall survival (median 54 vs. 35 months, P = .029).ConclusionHigh NaPi2b expression was noted in a significant subset of adenocarcinoma cases, and in particular amongst those who were TTF1+, or exhibited EGFR or KRAS mutations. This agrees with earlier reports and highlights the significance that NaPi2b may have a role as a possible target for delivery of cytotoxic agents via antibody-drug conjugate models for some patients with lung adenocarcinoma.     

Bleomycin-associated pulmonary fibrosis: rapidly fatal progression without chest radiotherapy

Two patients with carcinoma of the tonsil were treated with bleomycin (396 and 224 units, respectively) but not with radiotherapy. Respiratory insufficiency led to death 45 and 52 days, respectively, after onset of therapy. Chest radiographs before bleomycin therapy revealed no evidence for lung disease. Postmortem examinations showed severe interstitial and intraalveolar pulmonary fibrosis. Comparably rapid progression from radiographically normal pulmonary parenchyma to fatal fibrosis has been documented previously only in patients with thoracic neoplasia as well as, in all but one instance, either prior or concurrent chest radiotherapy. These two cases indicate that chest radiotherapy is not a necessary cofactor for the development of rapidly progressive, fatal, diffuse interstitial pulmonary fibrosis after bleomycin therapy.     

Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer

The prognosis of patients with stage III nonsmall cell lung cancer was studied, with special attention to their biologic status prior to lung resection. The biologic status was estimated from the neutrophil/lymphocyte ratio in the peripheral blood, serum albumin level, and erythrocyte sedimentation rate. Among 46 patients who underwent potentially curative operations, 31 cases of biologic status A or B (more than two parameters normal) revealed 37.6% of a 5-year survival rate, whereas there was no 5-year survivor in 15 cases of biologic status C or D (more than two parameters abnormal). Of the 5-year survival rate in T3N0 disease of biologic status A or B, the 60% surviving (of 10 cases) was in marked contrast to the same stage disease of biologic status C or D where only 1 patient (of 10 cases) was still surviving at more than 30 months. In 30 patients with T3N0, T3N1, and T2N2 diseases of biologic status A or B, where long-term survivors were derived, the 5-year survival rate in 30 patients of biologic status A or B was 36.6% in contrast to no long-term survivor in the same stage diseases of biologic status C or D (n = 25). We conclude that surgical results in stage III nonsmall cell lung cancer will be beneficial in patients of biologic status A or B, but nonbeneficial in patients with the same stage of biologic status C or D.     

电视辅助胸腔镜肺叶切除术治疗非小细胞肺癌的疗效观察

目的 比较电视胸腔镜下肺叶切除与开胸肺叶切除治疗早期非小细胞肺癌的临床效果.方法 收集81例初诊为早期非小细胞肺癌实施手术治疗的患者为研究对象,并将其分为2组:观察组和对照组.观察组给予胸腔镜肺叶切除术,对照组给予开胸肺叶切除术.比较2组患者手术时间、术中出血、术后拔管时间、住院时间及术后并发症情况.定期随访,比较患者术后3个月、6个月、12个月及3年的生活质量及3年生存率.结果 2组患者的手术时间、拔管时间无明显差异(P>0.05),但观察组患者术中出血及住院时间明显低于对照组(P<0.05).观察组患者有7例出现肺部感染,并发症发生率17.1%;对照组患者并发症合计16例,并发症发生率为40.0%.观察组并发症发生率明显低于对照组(P=0.022).术后第3个月、6个月观察组患者的生存质量明显高于对照组(P<0.05),术后第12个月2组患者的生存质量无明显差异(P>0.05).观察组3年生存率为29.3%,对照组的生存率为30.0%,差异无统计学意义(P=0.994).结论 电视胸腔镜下肺叶切除术治疗非小细胞肺癌,手术创伤小,术中出血少,术后并发症少,术后生存质量高,术后3年生存率与开胸肺叶切除术无明显差异,近期效果满意.     

逆行肺切除在肺癌继发肺脓肿治疗中的应用

目的:探讨逆行肺切除在肺癌继发肺脓肿治疗中应用的可行性。方法:回顾性分析16例肺癌继发肺脓肿患者术中采用逆行肺切除术,即先处理支气管后处理肺血管的临床资料。结果:全组无围手术期死亡,恢复良好。结论:逆行肺切除在肺癌继发肺脓肿外科治疗中是可行的。     

诱导性同步放化疗治疗侵袭性肺上沟瘤

目的分析同步放化疗(CRT)在NSCLC外科治疗的地位.方法回顾性总结1987～1996年外科手术的30例累及胸顶部的NSCLC,单纯手术组10例,手术+放疗组(RT)9例,含铂方案化疗+放疗组(CRT)11例.结果单纯手术组2、4年生存率分别为30%和20%, RT组为22% 和11%,CRT组为73% 和53%.单因素分析根治性(是与否比较,P=0.027)和诱导性治疗(单纯手术和RT与CRT比较,P=0.0173)是有意义的预后因素.多因素分析仅诱导性治疗,P=0.023 8,是有意义的预后因素.结论与诱导性放疗和单纯手术相比,CRT可提高累及胸顶部的NSCLC患者的生存率.